Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) reported Q3 EPS of ($0.13), $0.16 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $36.85 million.

For earnings history and earnings-related data on Sonnet BioTherapeutics Holdings, Inc. (SONN) click here.